A Phase 1 study of nemtabrutinib in hepatic impairment

Completed Phase 1 NCT06442436

Study Description

A study evaluating the effects of moderate liver impairment on a new drug called nemtabrutinib

Study Details

Registry ID:
NCT06442436
Conditions:
Hepatic Impairment (HI)
Phase:
Phase 1
Target Enrollment:
24 participants
Start Date:
Age Range:
18–75 years
Healthy Volunteers:
No

Study Locations (3 sites)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →